Choose Your Country or Region

Droxidopa

Name: Droxidopa
Brand: Selleck Chemicals
SKU: S3041
Rating: 5 (1 reviews)

Synonyms: L-DOPS

Catalog No.S3041 Purity:99.84%

Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Droxidopa Chemical Structure

CAS No. 23651-95-8

Purity & Quality Control

Batch: Purity: 99.84%

99.84

Droxidopa Related Products

Related Targets	α-adrenergic receptor β-adrenergic receptor Beta-Adrenergic Receptor	Click to Expand
Related Products	Zenidolol (ICI-118551) Hydrochloride Yohimbine HCl L755507 Atipamezole Higenamine hydrochloride Fenoterol hydrobromide Medetomidine HCl Rauwolscine hydrochloride Deoxycorticosterone acetate Detomidine HCl Naftopidil	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I GPCR Compound Library	Click to Expand

Signaling Pathway

Adrenergic Receptor Signaling Pathway

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2 cells	Function assay		24 h		Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis, EC50=0.004 μM	20966043
Click to View More Cell Line Experimental Data

Biological Activity

Description

Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Features

An artificial amino acid.

Targets

Adrenergic Receptor ^[1]

In vitro
In vitro	Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. ^[1] Droxidopa is well tolerated. ^[2] Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure. ^[3] Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. ^[4]

In Vivo
In vivo	The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow. Droxidopa-treated rats also showed a decreased ratio of p-eNOS/eNOS and p-AKT/AKT and increased activity of RhoK in SMA^[5].
Animal Research	Animal Models	biliary duct-ligated (BDL) rats
	Dosages	25-50 mg/kg
	Administration	oral administration

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT03446807	Withdrawn	Parkinson Disease\|Multiple System Atrophy\|Progressive Supranuclear Palsy	Loma Linda University\|H. Lundbeck A/S	December 2021	Phase 2
NCT04977388	Recruiting	Menkes Disease\|Occipital Horn Syndrome	Stephen G. Kaler MD\|Nationwide Children''s Hospital	July 12 2021	Phase 1\|Phase 2
NCT03173781	Completed	Parkinson''s Disease	Colorado Springs Neurological Associates\|H. Lundbeck A/S	April 2016	Not Applicable
NCT01331122	Withdrawn	Gait Disorders Neurologic	Chelsea Therapeutics	April 2012	Phase 1\|Phase 2
NCT01354158	Completed	Spinal Cord Injury\|Hypotension	Bronx VA Medical Center\|Chelsea Therapeutics	May 2011	Phase 1
NCT01327066	Completed	QTc Interval	Chelsea Therapeutics	March 2011	Phase 1

References

+ Expand

Chemical Information & Solubility

Molecular Weight	213.19	Formula	C₉H₁₁NO₅
CAS No.	23651-95-8	SDF	Download Droxidopa SDF
Smiles	C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 2 mg/mL ( (9.38 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 2 mg/mL

Ethanol : Insoluble

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.				In vivo Formulation Calculator
Clear solution	saline	2.000mg/ml (9.38mM)	Taking the 1 mL working solution as an example, add 2 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	saline	1.000mg/ml (4.69mM)	Taking the 1 mL working solution as an example, add 1 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):